BioCheetah

What BioCheetah does

BioCheetah Pte Ltd is a Singapore-based diagnostics company spun out from A*STAR's Institute of Molecular and Cell Biology (IMCB) that develops non-invasive, protein-based immunodiagnostic applications for bladder cancer detection. The company's flagship product is the VECanDx™ ELISA Test, a urine-based laboratory assay that measures five patented protein biomarkers using proprietary rabbit monoclonal detection antibodies and converts those measurements into a single bladder cancer risk score through a proprietary algorithm. A Point-of-Care Testing (POCT) lateral-flow kit is also under development for qualitative bedside use by general practitioners and polyclinics. The company's biomarker IP and detection antibodies are exclusively licensed from A*STAR, anchoring both the ELISA and POCT products on the same proprietary biomarker panel.

The business model combines direct sales to hospitals and laboratories with regional licensing and distribution. The VECanDx™ ELISA is commercialized through Wellesta Holdings across ASEAN, the Indian sub-continent, MENA, the EU, and LATAM, and through an exclusive license to Nippon Kayaku Co., Ltd. for Japan — the latter covering local clinical trials, regulatory applications, distribution, and sales, with BioCheetah receiving upfront and milestone payments. BioCheetah also runs clinical validation partnerships with Singapore General Hospital and hospitals in China and France, and is pursuing regulatory approvals from Singapore's Health Sciences Authority and the US FDA 510(k) process to transition the product from a lab-developed test to a fully registered IVD.

BioCheetah is ISO 13485:2016 certified (TÜV SÜD) for medical device design and development and operates a pilot production facility at LaunchPad @ One-North in Singapore alongside its R&D operations at Biopolis. The company employs between 1-10 people, has not disclosed institutional funding rounds, and targets the global bladder cancer market — the 10th most common cancer worldwide with approximately 549,000 new cases and 200,000 deaths annually — where its products position as a non-invasive liquid-biopsy alternative to invasive cystoscopy.

Name

BioCheetah

Legal name

BioCheetah Pte Ltd

Website

https://biocheetah.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

BioCheetah is a Singapore-based A*STAR-IMCB spin-off that develops non-invasive, urine-based immunodiagnostic tests for bladder cancer, commercializing its flagship VECanDx™ ELISA and pipeline POCT kit via regional partners.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Bladder cancer diagnostics
• Non-invasive diagnostics
• Immunodiagnostic tests
• ELISA test kits
• Cancer biomarker discovery

Headquarters

HQ city

Bukit Merah

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. VECanDx™ ELISA Product Sales: Sale of IVD ELISA test kits to hospitals, laboratories and healthcare providers for bladder cancer detection and monitoring. Currently available as lab-developed test (LDT) with upcoming IVD launch.
2. Licensing and Milestone Payments: Upfront and milestone payments from Nippon Kayaku upon signing and commercialization of VECanDx™ in Japan under exclusive licensing agreement.
3. Distribution Partnership Revenue: Revenue from Wellesta partnership for commercialization of VECanDx™ ELISA test across ASEAN, Indian sub-continent, MENA, EU and LATAM markets.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

BioCheetah develops and commercializes non-invasive, protein-based immunodiagnostic applications, primarily for bladder cancer detection. Its flagship product is VECanDx™, an ELISA-based IVD test kit that measures five patented urinary protein biomarkers using proprietary rabbit monoclonal detection antibodies and converts those measurements into a single risk score via a proprietary algorithm. The company serves hospitals, clinical laboratories, and (in development) general practitioners with non-invasive urine-based testing as an alternative to cystoscopy.

Product overview

BioCheetah offers a portfolio of non-invasive, protein-based immunodiagnostic products for bladder cancer detection. The flagship product, VECanDx™ ELISA Test, is an ELISA-based IVD kit that detects five patented urinary protein biomarkers and uses a proprietary algorithm to generate a risk score for bladder cancer diagnosis. The company also has a Point-of-Care Testing (POCT) Kit in its pipeline, which utilizes lateral flow immunoassay technology for rapid qualitative analysis. Both products target bladder cancer detection in hematuria patients and high-risk individuals through non-invasive urine sampling.

Differentiator

Problem solved

Functional benefit

Products and services

• VECanDx™ ELISA Test A non-invasive Enzyme-Linked Immunosorbent Assay (ELISA)-based IVD test that measures five patented protein biomarkers in urine samples using proprietary rabbit monoclonal detection antibodies. A proprietary algorithm converts biomarker measurements into a single risk score for non-invasive detection and monitoring of bladder cancer in adults with hematuria or history of bladder cancer. Intended for use by hospitals, clinical laboratories, and urology specialists.

Quantifiable outcome

• Five novel biomarkers with high sensitivity and specificity for bladder cancer detection
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Nippon Kayaku Co., Ltd.coreOEM/ Whitelabel/ Licensing Partner · 15 December 2023BioCheetah granted Nippon Kayaku exclusive rights to develop and market VECanDx™ ELISA for bladder cancer diagnosis in Japan. BioCheetah continues clinical trials in Singapore, France and China while Nippon Kayaku handles Japanese clinical trials, regulatory application, distribution and sales. BioCheetah receives upfront and milestone payments upon signing and commercialization.
• Wellesta Holdings Pte LtdcoreChannel Partner/ Reseller/ Distributor · 26 September 2023Strategic partnership for commercialization of VECanDx™ ELISA test for early detection of bladder cancer. Wellesta sells, markets and distributes the product in ASEAN, Indian sub-continent, MENA, EU and LATAM countries. The partnership supports early-stage screening of bladder cancer and brings efficient, robust screening tools to market.
• A*STAR (Agency for Science, Technology and Research)coreOthersA*STAR-IMCB spin-off company with exclusive licensing of intellectual property for bladder cancer biomarkers and detection antibodies from A*STAR.
• Singapore General HospitalminorOthersClinical validation partner for bladder cancer diagnostic products. Hospital partnership for conducting clinical trials to validate diagnostic accuracy of urinary immunodiagnostic test kits.
• Hospitals in ChinaminorOthersInternational clinical trial partnerships with hospitals in China for validation of bladder cancer diagnostic products.
• Hospitals in FranceminorOthersInternational clinical trial partnerships with hospitals in France for validation of bladder cancer diagnostic products.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Exact Sciences: Public cancer diagnostics leader (Cologuard) with expanding multi-cancer screening pipeline. Comparable as a commercial-stage cancer diagnostics company using proprietary biomarkers with non-invasive sample collection.
• F. Hoffmann-La Roche: Major diagnostics incumbent with extensive immunoassay and IVD platforms serving oncology and urology. Comparable as a broad incumbent whose immunoassay-based diagnostic kits compete in the same hospital laboratory channels BioCheetah targets.
• Abbott (Diagnostics): Global diagnostics incumbent offering UroVysion FISH test for bladder cancer alongside a broad IVD portfolio. Comparable as an established player in the same clinical application (bladder cancer diagnostics), though via a wider product set.
• Phadia (Thermo Fisher Scientific): Major immunoassay diagnostics provider under Thermo Fisher, offering automated allergy and specialty IVD platforms. Comparable as a broad incumbent operating immunoassay-based diagnostics that share BioCheetah's core detection modality.
• Bio-Techne: Life science tools and diagnostics company providing biomarker antibodies, ELISA kits, and assay platforms. Comparable in antibody-based immunoassay technology and biomarker product offering relevant to BioCheetah's detection chemistry.
• Cepheid (Danaher): Molecular diagnostics subsidiary of Danaher with GeneXpert systems widely deployed in hospitals worldwide. Comparable as an established IVD platform vendor competing for hospital laboratory budgets relevant to BioCheetah's commercialization channels.

Direct peers

• Pacific Edge Diagnostics: New Zealand-based diagnostics company with Cxbladder, a non-invasive urine-based test for bladder cancer detection and surveillance. Directly comparable to BioCheetah's VECanDx™ in product category, target market, and clinical use case.
• MDxHealth: Commercial-stage diagnostics company offering non-invasive urine and tissue tests for urological cancers, including bladder cancer. Directly comparable in product modality (urine biomarker assays), customer base (urologists/hospitals), and regulatory/IVD commercialization model.

Emerging players

• Nucleix: Liquid biopsy company developing non-invasive epigenetic cancer diagnostics including urological cancers. Comparable as an emerging liquid biopsy peer pursuing non-invasive cancer detection via proprietary biomarkers.
• Nonagen Bioscience: Diagnostics developer focused on non-invasive cancer detection including bladder cancer (Oncuria™ multiplex urine biomarker assay). Comparable as a smaller, biomarker-driven bladder cancer diagnostics peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biocheetah-pte-ltd

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioCheetah